The dual T-cell agonist invikafusp alfa achieved a 50% DCR in heavily pretreated anti–PD-1/PD-L1–resistant tumors, per findings at the 2024 SITC Annual Meeting.
The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney DiseasePlans to Initiate Rare Kidney Diseases Cohort in Early ...
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...
The Philippine Health Insurance Corporation (PhilHealth) on Friday launched additional and expanded health benefit packages ...
The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...
An expert panel has developed a hospital care plan for Parkinson disease to avoid preventable harm among patients.
Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter ...
Scientists at the University of Copenhagen have uncovered a breakthrough in understanding Parkinson’s disease (PD), a ...
BIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback